Home » Stocks » Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd. (KNSA)

Stock Price: $22.09 USD -0.37 (-1.65%)
Updated Jul 16, 2020 1:27 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.33B
Revenue (ttm) n/a
Net Income (ttm) -122.47M
Shares Out 25.10M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $22.09
Previous Close $22.46
Change ($) -0.37
Change (%) -1.65%
Day's Open 22.18
Day's Range 21.56 - 22.50
Day's Volume 182,503
52-Week Range 5.01 - 28.67

More Stats

Market Cap 1.33B
Enterprise Value 1.13B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.10M
Float 19.06M
EPS (basic) -2.22
EPS (diluted) -2.23
FCF / Share -2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.79M
Short Ratio 9.02
Short % of Float 12.95%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.06
Revenue n/a
Operating Income -131.70M
Net Income -122.47M
Free Cash Flow -128.77M
Net Cash 202.18M
Net Cash / Share 3.36
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.77%
ROE -47.81%
ROIC -75.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(69.31% upside)
Current: 22.09
Target: 37.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-170-108-65.40-24.00
Net Income-162-103-64.87-23.97
Shares Outstanding54.0529.551.810.26
Earnings Per Share-2.99-3.49-35.85-91.61
Operating Cash Flow-158-81.01-50.22-21.87
Capital Expenditures-3.20-5.29-0.07-
Free Cash Flow-162-86.30-50.29-21.87
Cash & Equivalents23430845.6656.08
Total Debt2.65---
Net Cash / Debt23130845.6656.08
Book Value225279-89.71-25.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kiniksa Pharmaceuticals Ltd.
Country Bermuda
Employees 135
CEO Sanj K. Patel

Stock Information

Ticker Symbol KNSA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KNSA
IPO Date May 24, 2018


Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.